ABBV EPS
Net income divided by diluted shares outstanding — the per-share profit earned each quarter.
EPS
Latest: $2.03 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.29 |
| 2020Q4 | -$0.13 |
| 2021Q1 | $1.99 |
| 2021Q2 | $0.42 |
| 2021Q3 | $1.78 |
| 2021Q4 | $2.26 |
| 2022Q1 | $2.51 |
| 2022Q2 | $0.51 |
| 2022Q3 | $2.21 |
| 2022Q4 | $1.40 |
| 2023Q1 | $0.13 |
| 2023Q2 | $1.14 |
| 2023Q3 | $1.00 |
| 2023Q4 | $0.45 |
| 2024Q1 | $0.77 |
| 2024Q2 | $0.77 |
| 2024Q3 | $0.88 |
| 2024Q4 | -$0.03 |
| 2025Q1 | $0.72 |
| 2025Q2 | $0.52 |
| 2025Q3 | $0.10 |
| 2025Q4 | $1.02 |
| 2026Q1 | $0.39 |
| 2026Q2 | $2.03 |
Other ABBV Charts
More quarter-by-quarter fundamentals for AbbVie Inc.
1 / 10
Revenue
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Latest EPS: $2.03 (2026Q2); +290.4% YoY; +9.6% CAGR since 2013Q1 (13.25y).
Across the 54 quarters from 2013Q1 to 2026Q2, EPS ranged from -$1.15 in 2018Q4 to $2.51 in 2022Q1.
Chart and table show the latest 24 of 54 quarters.